Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Allergan Inc | 452 |
| 2 | Theravance Biopharma R&D IP LLC | 234 |
| 3 | Merck Sharp & Dohme LLC | 220 |
| 4 | Merck and Co Inc | 219 |
| 5 | Purdue Pharma LP | 194 |
| 6 | Alcon Inc | 189 |
| 7 | Euro Celtique SA | 185 |
| 8 | AstraZeneca AB | 151 |
| 9 | Novartis AG | 141 |
| 10 | Santen Pharmaceutical Co Ltd | 116 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 10,377 |
| 2 | A61K | Medicinal preparations | 9,464 |
| 3 | C07D | Heterocyclic compounds | 4,571 |
| 4 | C07K | Peptides | 1,459 |
| 5 | A61F | 1,412 |
| 6 | C07C | Acyclic and carbocyclic compounds | 1,210 |
| 7 | A61M | Devices for introducing media into the body | 803 |
| 8 | C12N | Microorganisms, enzymes | 767 |
| 9 | G01N | Investigating / analysing materials | 731 |
| 10 | A61L | Sterilising / disinfecting materials | 639 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Indole beta-site alkylation method without participation of transition metal | 2021 | JIANGSU UNIVERSITY OF SCIENCE AND TECHNOLOGY | 1 |
| A-pi-D type donor photovoltaic material formed by connecting porphyrin single beta site through double bonds, and preparation and application thereof | 2023 | SOUTH CHINA UNIVERSITY OF TECHNOLOGY | 0 |
| COMPOUNDS AND THEIR USE AS BETA SITE APP CLEAVING ENZYME (BACE) INHIBITORS | 2017 | ASTRAZENECA AB | 0 |
| IMINOTIADIAZINE DIOXIDE COMPOUNDS AS BETA SITE APP DISOCIATION ENZYME INHIBITORS (BACE), COMPOSITIONS, AND ITS USE | 2017 | MERCK SHARP & DOHME CORP | 0 |
| PROCEDURE FOR PREPARING FOR THE ALFA. BETA SITE ETHENICALLY UNSATURATED CARBOCYCLIC KETONES FROM ENOLLACTONES. | 1975 | SYNTEX CORPORATION, PANAMA. | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Glaucoma and retinal disorders | 6 |
| 2 | Autoimmune Bullous Skin Diseases | 1 |
| 3 | Non-Invasive Vital Sign Monitoring | 1 |
| 4 | Ocular Surface and Contact Lens | 1 |
| 5 | Poisoning and overdose treatments | 1 |
| 6 | Receptor Mechanisms and Signaling | 1 |
| 7 | Retinal Diseases and Treatments | 1 |
| 8 | Urinary Bladder and Prostate Research | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gary D. Novack | University of California, Irvine | 28 |
| 2 | Efraim Duzman | University of California, Irvine | 9 |
| 3 | Elaine P. Kelley | Allergan (United States) | 9 |
| 4 | Franz-Josef Leinweber | Wake Forest University | 7 |
| 5 | John Lue | Allergan (United States) | 7 |
| 6 | Diane Tang‐Liu | Allergan (Ireland) | 5 |
| 7 | Frederick J. Di Carlo | Wake Forest University | 5 |
| 8 | Hideaki Kohri | Otsuka (Japan) | 5 |
| 9 | Kwou‐Yeung Wu | Kaohsiung Medical University | 5 |
| 10 | Charles F. Schwender | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy. | 1994 | 189 | Glaucoma and retinal disorders |
| Extracapsular cataract extraction with posterior chamber lens implantation in primary angle-closure glaucoma | 1997 | 96 | Glaucoma and retinal disorders |
| Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. | 1995 | 82 | Glaucoma and retinal disorders |
| Allergic reactions to brimonidine in patients treated for glaucoma | 2002 | 65 | Glaucoma and retinal disorders |
| Correlates of acute exercise-induced ocular hypotension. | 1994 | 63 | Non-Invasive Vital Sign Monitoring |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Akbeta?
Which companies hold the most patents related to this compound?
What research topics are most associated with Akbeta in the academic literature?
Who are the most prolific authors in Akbeta research?
What is the distribution of patents by CPC classification for this compound?